CRLF2 Specific Neutra™ Antibody Products

Struggling with prolonged therapeutic development timelines or inconsistent targeting of CRLF2 in hematologic malignancies? Creative Biolabs' CRLF2 specific Neutra™ antibody products overcome these hurdles using advanced recombinant engineering and epitope-specific validation, enabling rapid identification of CRLF2-driven pathologies and accelerating translational research.

Introduction to CRLF2

Cytokine receptor-like factor 2 (CRLF2) is a transmembrane protein belonging to the type I cytokine receptor family. It forms heterodimers with interleukin-7 receptor α (IL-7Rα) or thymic stromal lymphopoietin receptor (TSLPR) to mediate pro-survival and proliferative signaling. CRLF2 is frequently overexpressed in hematologic cancers, particularly B-cell acute lymphoblastic leukemia (B-ALL), and is linked to aggressive disease subtypes. Its dysregulation via chromosomal rearrangements (e.g., CRLF2 fusions or IKZF1 deletions) drives oncogenesis by constitutively activating downstream pathways.

Fig.1 The CRLF2 receptor complex and downstream pathways.¹

• Structure

CRLF2 comprises an extracellular cytokine-binding domain, a single transmembrane helix, and an intracellular domain lacking intrinsic kinase activity. Its extracellular region contains four conserved fibronectin type III domains critical for ligand interaction. Dimerization with IL-7Rα or TSLPR triggers conformational changes, exposing Janus kinase (JAK) binding sites on intracellular domains. Structural studies reveal that CRLF2-JAK2 complexes adopt unique orientations to initiate signal transduction, making these interfaces prime targets for therapeutic intervention.

• Related Signaling Pathways

CRLF2 activates JAK-STAT, PI3K-AKT, and MAPK pathways upon ligand binding. In B-ALL, CRLF2 overexpression induces hyperactivation of STAT5, promoting uncontrolled cell proliferation and resistance to apoptosis. Cross-talk with mTOR further enhances metabolic reprogramming in malignant cells. CRLF2 signaling also modulates immune evasion in solid tumors by upregulating PD-L1 expression via STAT3, highlighting its dual role in cancer progression and immunosuppression.

• Associated Diseases

CRLF2 aberrations are hallmark features of high-risk B-ALL, particularly in pediatric and Down syndrome-associated leukemias. Over 15% of Philadelphia chromosome-like (Ph-like) ALL cases harbor CRLF2 rearrangements, correlating with poor prognosis and chemotherapy resistance. CRLF2 is also implicated in T-cell lymphomas, autoimmune disorders, and inflammatory conditions, underscoring its broad therapeutic relevance.

Applications of CRLF2 Neutralizing Antibodies

• Diagnostic Profiling in Hematologic Malignancies

CRLF2-specific antibodies are critical for identifying high-risk B-ALL subtypes via immunohistochemical staining of bone marrow biopsies. Their high specificity differentiates CRLF2-overexpressing clones from normal hematopoietic cells, aiding in risk stratification and minimal residual disease (MRD) monitoring.

• Targeted Therapy Development

Neutralizing antibodies suppress CRLF2-mediated signaling in xenograft models, reducing tumor burden and improving survival rates. They synergize with JAK inhibitors to overcome resistance in Ph-like ALL, offering combinatorial strategies for refractory cases.

• Biomarker Discovery for Immunotherapy

CRLF2 expression levels predict response to JAK/STAT inhibitors in clinical trials. Antibody-based assays quantify CRLF2 in liquid biopsies, facilitating real-time monitoring of therapeutic efficacy and relapse potential.

• Preclinical Evaluation of CAR-T Cell Therapies

Anti-CRLF2 antibodies validate target engagement in chimeric antigen receptor (CAR) T-cell development. They enhance CAR-T specificity by confirming CRLF2 surface expression on leukemic cells while sparing healthy tissues.

Our Anti-CRLF2 Antibodies

Neutralizing antibodies targeting CRLF2 block ligand-receptor interactions or disrupt dimerization, effectively inhibiting oncogenic signaling. Creative Biolabs' CRLF2 specific antibodies exhibit nanomolar affinity for conformational epitopes, validated in flow cytometry, immunohistochemistry (IHC), and biofunctional assays. These antibodies enable precise detection of CRLF2 overexpression in patient samples and robust inhibition of STAT5 phosphorylation in preclinical models, supporting drug discovery and companion diagnostics.

Creative Biolabs' CRLF2 specific Neutra™ antibody products are engineered to deliver unmatched specificity and reproducibility for oncology and immunotherapy research.

Contact our team today to explore tailored solutions for your CRLF2-focused projects.

REFERENCE

1. Shiraz, Parveen, Kimberly J. Payne, and Lori Muffly. "The current genomic and molecular landscape of Philadelphia-like acute lymphoblastic leukemia." International Journal of Molecular Sciences 21.6 (2020): 2193. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/ijms21062193